Dr. Michael Harrison is Professor Emeritus of Surgery and Pediatrics and the Director Emeritus of the Fetal Treatment Center at UCSF. He graduated cum laude from Yale University and magna cum laude from Harvard Medical School. He completed his surgical training at the Massachusetts General Hospital in Boston and his pediatric surgery fellowship at Children's Hospital of Los Angeles. He is board certified in Surgery, Pediatric Surgery, and Critical Care.
Dr. Harrison and his surgery associates confine their surgical practice exclusively to children with special interest in fetal surgery, in repair of complex birth defects involving the chest, lung, abdomen, bowel, and bladder, and surgical care of children from birth through adolescence. Dr. Harrison and his associates, The Bay Area Pediatric Surgeons, do consultations and provide surgical care at Moffitt/Long Hospitals UCSF, California Pacific Medical Center, and Kaiser Permanente, San Francisco.
Dr. Harrison has a special interest in fetal surgery which he has pioneered with his colleagues at UCSF. For the past 18 years Dr. Harrison has studied the pathophysiology and natural history of a number of life-threatening fetal abnormalities including congenital diaphragmatic hernia, congenital cystic adenomatoid malformation of the lung, sacrococcygeal teratoma, fetal obstructive uropathy, and myelomeningocele. He has developed techniques for both in-utero open fetal surgery and endoscopic surgical repair (FETENDO Fetal Surgery)of many fetal abnormalities. In addition, Dr. Harrison's team has developed in-utero stem cell transplantation to treat immunodeficiencies, enzyme deficiencies, and hemoglobinopathies. Dr. Harrison leads the multidisciplinary UCSF Fetal Treatment Center Team that has developed an international reputation for treating complex birth defects before and after birth. (Referrals can be made to 1-800-RX-FETUS.)
Dr. Harrison, his wife Gretchen, and four children have lived in San Francisco for the past 20 years.
Most recent publications from a total of 433
Harrison MR, Ramalingam S. Novel Androgen Receptor Signaling Inhibitors for Nonmetastatic Castration-Resistant Prostate Cancer: The Light at the End of the Tunnel-or an Oncoming Train? Oncology (Williston Park). 2016 Apr 15; 30(4). View in PubMed
Ramalingam S, Pollak KI, Zullig LL, Harrison MR. What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis? Oncology (Williston Park). 2015 Sep; 29(9). View in PubMed
Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR. Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. J Oncol Pract. 2015 Nov; 11(6):491-7. View in PubMed
Liao A, Lin MC, Ritz LC, Swisher SL, Ni D, Mann K, Khan Y, Roy S, Harrison MR, Arias AC, Subramanian V, Young D, Maharbiz MM. Impedance sensing device for monitoring ulcer healing in human patients. Conf Proc IEEE Eng Med Biol Soc. 2015 Aug; 2015:5130-3. View in PubMed
Davis K, Wood S, Dill E, Yuri Fesko YF, Bitting RL, Harrison MR, Armstrong AJ, Moul JW, George DJ. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution. Clin J Oncol Nurs. 2015 Jun 1; 19(3):297-303. View in PubMed
Harrison MR, Bussmann J, Huang Y, Zhao L, Osorio A, Burns CG, Burns CE, Sucov HM, Siekmann AF, Lien CL. Chemokine-guided angiogenesis directs coronary vasculature formation in zebrafish. Dev Cell. 2015 May 26; 33(4):442-54. View in PubMed
Swisher SL, Lin MC, Liao A, Leeflang EJ, Khan Y, Pavinatto FJ, Mann K, Naujokas A, Young D, Roy S, Harrison MR, Arias AC, Subramanian V, Maharbiz MM. Impedance sensing device enables early detection of pressure ulcers in vivo. Nat Commun. 2015; 6:6575. View in PubMed
Stover JT, Moore RA, Davis K, Harrison MR, Armstrong AJ. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015 Jun; 18(2):161-6. View in PubMed
Iqbal CW, Wall J, Harrison MR. Challenges and climate of business environment and resources to support pediatric device development. Semin Pediatr Surg. 2015 Jun; 24(3):107-11. View in PubMed
Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2015 Aug; 13(4):392-9. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.
UCSF Surgical Innovations Program - October 23, 2015
Two (2) Department of Surgery research teams were awarded seed funding totaling $40,000 to accelerate their medical device innovations. The Roboimplant device, an expandable rod for orthopaedic surgery applications, took top honors, with the Sentinel Bandage, a non-invasive technology for wound monitoring, taking second place. The awards were given at the UCSF Surgical Innovations Program's inaugural Shark Tank competition on September 24th at UCSF Mission Bay.
Four teams of finalists pitched [...]
UCSF News reports on the discovery by researchers at UCSF Benioff Children's Hospital San Francisco that fetuses with enlarged ventricles, the fluid-filled cavities inside the brain, may be less likely than other fetuses to benefit from surgery in the womb to treat spina bifida. These findings were based on data from the 2011 Management of Myelomeningocele (MOMS) study, which demonstrated the potential benefit of treating spina bifida, a birth defect, in utero.
The researchers found that [...]
UCSF Surgical Innovations Program - March 17, 2015
UC Berkeley News reports on the "smart bandage," a device in development by a team of surgeons and scientists at UCSF and UC Berkeley that uses electrical currents to detect early tissue damage from pressure ulcers, or bedsores, well before they are visible to the human eye. The technology offers the possibility of early intervention to prevent progression of the wound. David M. Young, MD, Professor in the Division of Plastic and Reconstructive Surgery, is leading the clinical development of [...]
"Innovation in medicine is driven by need, but also by the market," said Dr. Michael R. Harrison, the director emeritus of the Fetal Treatment Center and the director of the Pediatric Device Consortium, both at the University of California, San Francisco. "Big markets have lots of folks developing devices, but small markets like the pediatrics market don't."
Michael R. Harrison, MD, founder and director emeritus of the Fetal Treatment Center at the UCSF Benioff Children's Hospital, was recognized last week for his contributions to life-saving fetal surgery with the Ronald McDonald House Charities Medical Award of Excellence.
Surgeons at the UCSF Benioff Children's Hospital in San Francisco are using magnets to reshape the breastbones of children who suffer from Sunken Chest Syndrome. The technique is undergoing phase 3 clinical trials, but the doctors hope to prove that long term magnetic force is as effective and less painful than conventional surgery.
A new method for repairing Pectus Exacavatum using magnets and an external brace, developed by Michael Harrison, a pediatric surgeon at the University of California, San Francisco's Benioff Children's Hospital, could provide an alternative to the surgery.
UCSF has received about a million dollars since 2009. That money has supported the development of tools to treat scoliosis, kidney failure and sunken chest, among other conditions. The pectus, or sunken chest device, is in clinical trials.
The UCSF "D'Vice Squad," a group of innovators from across the Bay Area, has drawn from diverse disciplines over the last two years to develop medical devices for children.
Now the squad's hard work has been rewarded with a $1 million grant from the U.S. Food and Drug Administration (FDA) to expand its work over the next two years.
For years, surgeons have been seeking ways of operating on babies in the womb, reasoning that medical abnormalities are easier to address while the fetus is still developing. Now, for the first time, a large clinical trial has shown that fetal surgery can also benefit infants with non life-threatening conditions. The eight-year study reported in the New England Journal of Medicine, found that babies born with myelomeningocele, the most common form of spina bifida, a debilitating spinal [...]
UCSF announces the formation of the Institute for Fetal and
Neonatal Health symposium brings together clinicians and basic
scientists involved in different aspects of development and fetal
Stopping curvature of the spine in kids usually requires a series of painful operations to implant rods and screws to adjust the spine. Even then, the results are often less than perfect. However, a medical team at UCSF has developed a technique using magnets that promises to do away with so many surgeries.
In our efforts to establish a distinguished professorship in honor of Michael R. Harrison, M.D, an extremely generous donor has called for a challenge. The anonymous donor has pledged a gift of $500,000 in the form of a match. Our goal must be met by Dec 31, 2009.
Michael Harrison M.D., a renowned pioneer in fetal and pediatric surgery, Professor Emeritus of Surgery and Pediatrics, and Director Emeritus of the Fetal Treatment Center at UCSF, has been elected to the prestigious Institute of Medicine (IOM), one of the U.S. National Academies. Membership in the IOM reflects "the height of professional achievement and commitment to service" and is reserved for those at the pinnacle of their field.